GSA Capital Partners’s Axsome Therapeutics AXSM Stock Holding History

GSA Capital Partners’s Portfolio AXSM Stock Details AXSM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$404K	Sell	2,389 -6,728	-74%	-$1.16M	0.03%	1051
2025 Q4	$1.67M	Buy	9,117 +4,350	+91%	+$607K	0.14%	142
2025 Q3	$579K	Buy	+4,767	New	+$537K	0.05%	747
2025 Q2	–	Sell	-3,873	Closed	-$452K	–	1744
2025 Q1	$452K	Buy	+3,873	New	+$441K	0.04%	868
2022 Q4	–	Sell	-10,916	Closed	-$487K	–	1458
2022 Q3	$487K	Buy	+10,916	New	+$545K	0.06%	583
2022 Q2	–	Sell	-18,656	Closed	-$772K	–	1399
2022 Q1	$772K	Buy	18,656 +10,699	+134%	+$332K	0.1%	292
2021 Q4	$301K	Buy	+7,957	New	+$293K	0.04%	926
2021 Q3	–	Sell	-9,366	Closed	-$632K	–	1414
2021 Q2	$632K	Buy	+9,366	New	+$562K	0.07%	483

Other funds holding AXSM

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

GSA Capital Partners's AXSM Position: Q1 2026 in Review

GSA Capital Partners reduced its Axsome Therapeutics (AXSM) stake by 74% in Q1 2026, selling an estimated $1.16M and leaving 2,389 shares worth $404K. The position accounts for 0.03% of the portfolio, ranked #1051.

GSA Capital Partners first reported a position in AXSM in Q2 2021 and has held it in 8 quarters since. The position peaked at $1.67M in Q4 2025. 409 funds tracked by Wall St. Rank hold AXSM as of Q1 2026.

GSA Capital Partners held 2,389 shares of Axsome Therapeutics worth $404K as of Q1 2026.
GSA Capital Partners sold 6,728 Axsome Therapeutics shares in Q1 2026, an estimated $1.16M.
Axsome Therapeutics made up 0.03% of GSA Capital Partners's portfolio in Q1 2026, its #1051 holding.
GSA Capital Partners first reported a position in Axsome Therapeutics in Q2 2021 and has held it in 8 quarters since.
GSA Capital Partners's Axsome Therapeutics position peaked at $1.67M in Q4 2025.
409 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q1 2026.

Based on GSA Capital Partners's 13F filing for Q1 2026, filed 8 May 2026.